MyBDC is a new way to ensure the community’s voice is heard.
The therapy is for patients with severe and moderately severe hemophilia B.
These activities are the product of a collaboration between Medscape, NHF, the European Haemophilia Consortium and the World Federation of Hemophilia.
This new study will investigate if new therapies have resulted in better outcomes related to brain function in young hemophilia patients.
The winner of the 2018 MLB's Player's Choice Comeback Player of the Year Award selected NHF as his designated charity.
Nitya Bhattarai is an active champion of people with bleeding disordres. He is planning to pursue a degree in pharmacy studies.
Genentech responds to NHF and HFA questions regarding Hemlibra.
NHF and HFA continue to follow up on issues arising from Genentech’s recent announcement regarding reports of particulate matter in vials of Hemlibra.
This new approval represents an expansion of the therapy's initial VWD indication, which was granted by the FDA in 2009.
Today, Genentech provided the following statement regarding reports of particulate matter in vials of Hemlibra.